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A B S T R A C T
Chronic kidney disease (CKD) is clinically important in canine medicine. Current diagnostic tools lack
sensitivity for detection of subclinical CKD. The aim of the present study was to evaluate urinary
peptidome analysis for diagnosis of CKD in dogs. Capillary electrophoresis coupled to mass spectrometry
analysis demonstrated presence of approximately 5400 peptides in dog urine. Comparison of urinary
peptide abundance of dogs with and without CKD led to the identification of 133 differentially excreted
peptides (adjusted P for each peptide <0.05). Sequence information was obtained for 35 of these peptides.
This 35 peptide subset and the total group of 133 peptides were used to construct two predictive models
of CKD which were subsequently validated by researchers masked to results in an independent cohort of
20 dogs.
Both models diagnosed CKD with an area under the receiver operating characteristic (ROC) curve of
0.88 (95% confidence intervals [CI], 0.72–1.0). Most differentially excreted peptides represented
fragments of collagen I, indicating possible association with fibrotic processes in CKD (similar to the
equivalent human urinary peptide CKD model, CKD273). This first study of the urinary peptidome in dogs
identified peptides that were associated with presence of CKD. Future studies are needed to validate the
utility of this model for diagnosis and prediction of progression of canine CKD in a clinical setting.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic kidney disease (CKD) is defined as structural or
functional abnormalities of one or both kidneys, present for at
least three months (Polzin, 2017). This heterogeneous disease is
often not recognized until late in its course. Routine methods used
for CKD diagnosis include serum creatinine concentration and
urinalysis, evaluation of renal proteinuria, and diagnostic imaging.
Current non-invasive diagnostic methods are insensitive for early
detection of CKD, especially non-proteinuric disease (Bartges,* Corresponding author.
E-mail address: lena.pelander@slu.se (L. Pelander).
1 These authors contributed equally to this work.
https://doi.org/10.1016/j.tvjl.2019.05.010
1090-0233/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article un2012). Therefore, research with the aim of improving early
diagnosis of CKD in dogs is needed. Circulating indirect biomarkers
of decreased glomerular filtration rate (GFR) such as SDMA and
cystatin C can be used to diagnose CKD (Wehner et al., 2008;
Nabity et al., 2015). However, because of the immense compensa-
tory capacity of the kidneys, reduction in GFR, even if measured by
creatinine trending, renal clearance studies or by scintigraphy,
does not ensue until this compensatory adaption fails (Brown et al.,
1990) and therefore, these methods are not likely to represent a
reliable way of detecting renal compromise at an early point in
time. In recent years, several serum, plasma and urinary
biomarkers have been evaluated in dogs with both acute kidney
injury (AKI) and CKD for detection of kidney injury at an early point
in time (Monti et al., 2012; Nabity et al., 2012; Segev et al., 2013;
Hokamp et al., 2016).der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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use for diseases of the kidney and urinary tract (Decramer et al.,
2008). It has some advantages over alternative biological fluids in
that its peptide profile is relatively less complex, samples can be
obtained non-invasively, and because of the stability of the
samples following collection (minimal proteolysis; Mischak et al.,
2010b). In human medicine, urine has been explored using ‘omics’
analyses for identification of biomarkers of disease (Suthanthiran
et al., 2013; Lacroix et al., 2014; Boizard et al., 2016). Urinary
peptidomics (i.e. analysis of the low molecular weight proteome),
using capillary electrophoresis coupled to mass spectrometry
(CE–MS), represents a particularly useful tool to diagnose and
predict CKD in people (Schanstra and Mischak, 2015). The sample
preparation is robust and several thousands of peptides that
compose the human urinary peptidome can be identified by
employing standard operating protocols and normalization
procedures within approximately 1 h (Mischak et al., 2013). In
this context, a model containing 273 urinary peptide biomarkers,
CKD273, has been identified by CE–MS and shown to perform
better than urinary albumin in early detection and prediction of
progression of human CKD (Good et al., 2010; Schanstra et al.,
2015). This model is currently used in the PRIORITY trial
(NCT02040441) in Europe, in which diabetic patients are screened
for presence of early renal lesions (Siwy et al., 2016).
Several studies have investigated the urinary proteome in
healthy dogs or in dogs with kidney disease, but only two studies
have explored proteomics for the diagnosis of CKD (Forterre et al.,
2004; Nabity et al., 2011). However, no attempt to validate study
findings in a separate cohort of dogs was made in these studies. The
aim of the present study was to evaluate the ability of CE–MS-
based urinary peptidome analysis to discriminate between healthy
dogs and those with CKD. A secondary aim was to identify the
peptides included in the discriminating models.
Materials and methods
Study population
This observational study was performed at the Swedish University of
Agricultural Sciences in Uppsala, after approval by Uppsala ethical committee
(Approval Number C340/11, Approval date 16 December 2011; and Approval
Number C119414/15, Approval date 1 April 2015). All experiments were performed
in accordance with relevant guidelines and regulations and with informed consent
from dog owners. Dogs with a previous diagnosis of CKD and healthy dogs, of any
breed, bodyweight (BW) and age were prospectively recruited. Dogs were
considered to have a conclusive diagnosis of CKD if they had multiple renal cysts,
persistent (3 months) azotemia, persistent proteinuria, a persistently decreased
measured glomerular filtration rate (mGFR), or a combination thereof. Exclusion
criteria were the presence of other systemic or organ related disease. If receiving an
angiotensin converting enzyme inhibitor, the drug was withdrawn a week before
inclusion and reintroduced after study inclusion because of unknown effects of this
drug on the canine urinary peptidome. Dogs chronically medicated with other
drugs (except sodium pentosane polysulfate injections) were excluded, as were
dogs with bacteriuria. Oral administration of glycosaminoglycan supplements and
feeding a kidney diet was allowed. Healthy student-, client-, and staff-owned dogs
of various breeds and ages were included as controls, as were six healthy beagles
from a Swedish research institution. These beagles were considered free of kidney
disease based on the absence of clinical signs, a creatinine concentration within the
reference range and urinalysis, including semi-quantitative biochemical analysis,
sediment examination, protein-to-creatinine ratio (UPC), and kidney histology
without pathological lesions (light microscopy).
On the day of enrolment into the study, dogs (including all control dogs except
the six research beagles) underwent a physical examination, collection of venous
blood and urine, echocardiographic examination, abdominal ultrasound examina-
tion of the entire urinary tract, and a scintigraphic examination for calculation of
individual kidney mGFR. Dogs had to be clinically stable and fasted for 12 h on the
day of inclusion. Dogs with CKD were staged according to the International Renal
Interest Society (IRIS) classification system,2 based on stable serum creatinine2 See: International Renal Interest Society http://www.iris-kidney.com/guide-
lines/staging.html (Accessed 23 May 2019).concentration. According to guidelines for human clinical proteomics (Mischak
et al., 2007, 2010a) dogs were divided into two cohorts: a discovery cohort, in which
the clinical status of each dog was known to those performing the analyses and an
independent validation cohort, in which the clinical status of the dogs was
unknown to those performing the analyses.
Examinations of blood and urine
Blood drawn from the cephalic vein was transferred to the laboratory at the
University Animal Hospital for immediate hematological and biochemical analysis.
For most dogs, urine was obtained by cystocentesis at the time of abdominal
ultrasound examination. When cystocentesis was not possible (n = 8), fresh
spontaneously voided urine was obtained. No proteinase inhibitor was added to
the urine (Havanapan and Thongboonkerd, 2009). Urine was divided into aliquots,
and 5–10 mL was immediately used for analysis (dipstick and sediment
examinations, specific gravity, UPC and aerobic culture). Remaining urine was
stored immediately at 70 C. Urine from the six beagles had previously been
obtained by cystocentesis, snap frozen and stored at 70 C. Remaining urine from
the beagles had been cooled and analysed within 24 h (dipstick and sediment
examinations, specific gravity, UPC and aerobic culture).
Abdominal ultrasound examination and renal scintigraphy
Complete upper and lower urinary tract ultrasound examinations were
conducted according to a pre-defined protocol by radiologists (board certified or
in residency training) at the university animal hospital diagnostic imaging clinic.
Measurement of individual kidney GFR was performed by a board certified
radiologist after renal scintigraphy, using the plasma volume method as previously
described (Westgren et al., 2014). With the plasma volume method, the rate of
glomerular filtration is indexed to an estimation of plasma volume (Westgren et al.,
2014). A total (left + right kidney) mGFR <30.8 mL/min/L was considered subnormal
(Kampa et al., 2003, 2007).
Sample preparation
Urine samples from all dogs were shipped on dry ice to Inserm U1048, Toulouse,
France, and thawed immediately before use. A volume of 0.7 mL was diluted with
0.7 mL 2 M urea, 10 mM NH4OH and 0.02% sodium dodecyl sulphate (SDS). In order
to remove high molecular weight polypeptides, samples were filtered using
Centrisart ultracentrifugation filter devices (20 kDa molecular weight cut-off;
Sartorius) at 3000 g until 1.1 mL of filtrate was obtained. The filtrate was desalted
with PD-10 column (GE Healthcare) equilibrated in 0.01% NH4OH in HPLC-grade
water. The prepared samples were lyophilized and stored at 4 C. Shortly before
CE–MS analysis, lyophilised samples were resuspended in HPLC-grade water
(Merck KGaA). The preparation method has previously been described in more
detail (Theodorescu et al., 2006).
CE–MS analysis and data processing
CE–MS analysis was performed as previously described (Mischak et al., 2013).
Briefly, CE–MS analyses were performed using a Beckman Coulter Proteome Lab
PA800 capillary electrophoresis system (Beckman Coulter) on-line coupled to a
micrOTOF II MS (Bruker Daltonic). The electro-ionization sprayer (Agilent
Technologies) was grounded, and the ion spray interface potential was set to
–4.5 kV. Data acquisition and MS acquisition methods were automatically
controlled by the CE via contact-close-relays. Spectra were accumulated every
3 s, over a range of m/z 350–3000. In the next step the MosaiquesVisu software
package was applied to deconvolute mass spectral ion peaks, because ionization
produced ions at different charged states from the original urinary peptides. This
deconvolution step groups these differently charged ions into single peptides with
unique real mass. Only signals observed in a minimum of three consecutive
spectra with a signal-to-noise ratio of at least 4 were considered. Signals with a
calculated charge of 1+ were automatically excluded to minimize interference
with matrix compounds or drugs. Capillary electrophoresis migration time and
MS-detected mass were normalized by the definition of 950 clusters of peptides
covering a range of 17.23–47.74 min in CE migration time and 807–16,399 kDa in
molecular mass. Samples were normalized by peptide abundance (intensity)
calibration based on 141 endogenous internal urinary polypeptide standards
displaying the highest frequency and stability in all analysed samples, to
compensate for differences in hydration status and urine volume between dogs.
This procedure has been described previously for people (Good et al., 2010;
Dissard et al., 2013). Each polypeptide present in the list was defined by its
normalized migration time (min), molecular mass (kDa), and signal intensity
detected. Using a Microsoft Structured Query Language database, all detected
polypeptides were deposited, matched, and annotated in order to allow for
further comparison between groups. The criteria applied to consider a
polypeptide identical was that within different samples, the mass deviation
was lower than 50 ppm for masses <4 kDa, 150 ppm for masses >6 kDa, and
between 50–150 ppm for masses between 4 and 6 kDa. Acceptable migration time
deviation was between 1 and 2.5 min.
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Candidate biomarkers and other native peptides from dog urine were
sequenced using liquid chromatography (LC)–MS/MS and CE–MS/MS analysis
(Klein et al., 2014). All LC–MS/MS analysis experiments were performed on a
Dionex Ultimate 3000 RSLC nano flow system (Dionex). For CE–MS/MS, the
samples were injected under constant flow and pressure conditions at a pH of
2.2 to ensure that all peptides are positively charged. Both CE and LC were
directly interfaced with an LTQ-Orbitrap XL (Thermo Finnigan) using data-
dependent high-energy collisional dissociation (HCD) MS/MS sequencing of a
maximum of the top 20 ions. All resultant MS/MS data were analysed using
Proteome Discoverer 1.3 (activation type: HCD; min-max precursor mass:
790–6000; precursor mass tolerance: 10 ppm; fragment mass tolerance:
0.05 Da; S/N threshold: 1) and were searched against the Uniprot canine non-
redundant database without enzyme specificity. No fixed modifications were
selected, oxidation of methionine and proline were selected as variable
modifications. The peptide data were extracted using high confidence
peptides, defined by an Xcorr  1.9, a delta mass between experimental
and theoretical mass 5 ppm, absence of cysteine in the sequence (because
cysteines without reduction and alkylation form disulphide bonds), absence
of oxidized proline in protein precursors other than collagens or elastin, and
top one peptide rank filters.
For further validation of peptide identification, the strict correlation
between peptide charge at pH 2 and CE-migration time was utilized to
minimize false-positive identification rates (Zurbig et al., 2006). Calculated
CE-migration time of the sequence candidate based on its peptide sequence
(number of basic amino acids) was compared to the charges of the peptides
and the experimental CE-migration time. Peptides were accepted only if they
had a mass deviation below 90 ppm and a CE-migration time deviation
below 2 min.Fig. 1. Study design and capillary electrophoresis coupled to mass spectrometry (CE–MS
discovery phase and a validation phase. Urine from 30 dogs (15 healthy dogs and 15 wi
differentially secreted peptides (133P model). Of these peptides, 35 were identified by CE–
model. In the validation phase, the two different models were tested on an independent, 
showing the compiled datasets of 30 canine urine samples. Each peptide (n = 5398) was id
represented by the peak height. (c) Sequenced peptide (n = 35) pattern distinguishing dBiomarker selection and modelling
For the identification of candidate urinary biomarkers, the reported P-values
were calculated using the Wilcoxon rank-sum test (R software package, version
3.1.3) followed by adjustment for multiple testing (Benjamini and Hochberg, 1995).
Peptides that were detectable in at least 75% of dogs in one of the two groups
(healthy dogs vs. dogs with CKD) and reached an adjusted P < 0.05 were further
considered as relevant. An R-based (version 3.1.3) support vector machine (SVM)-
package and leave-one-out feature selection approach was used to generate
biomarker models. Sensitivity and specificity were calculated based on the number
of properly classified samples. The overall yield of the polypeptide pattern was
evaluated by receiver operating characteristic (ROC) and area under curve (AUC)
plots using the Prism 7.00 GraphPad software.
Results
Study design and canine data
In total, 50 dogs (25 dogs with CKD and 25 healthy dogs) were
included in the study. Clinical data for the 25 dogs with CKD are
summarized in Supplementary Table S1. The minimum number of
individuals to include in a discovery cohort in a proteomic study is 24
(Dakna et al., 2010) and therefore, 30 dogs (15 healthy dogs and 15
dogs with CKD) were included in the discovery cohort. Thus, 20 dogs
comprised the independent validation cohort (10 healthy dogs and
10 dogs with CKD). An attempt was made to accomplish an even
distribution of dogs in different IRIS CKD stages in the discovery- and) analysis of canine urine. (a) The analysis was performed in two separate phases: a
th chronic kidney disease [CKD]) was analysed, leading to the identification of 133
MS/MS and liquid chromatography (LC)–MS/MS sequencing and included in the 35P
masked cohort of dogs (n = 20) to evaluate their predictive value. (b) Peptide pattern
entified based on CE migration time and specific mass (kD), with relative abundance
ogs with CKD from healthy dogs.
Fig. 2. Distribution scores of urinary peptide models for dogs with chronic kidney disease (CKD) vs. healthy dogs in the discovery cohort. (a) 133P model, (b) 35P model.
****P < 0.0001 vs. healthy dogs, Mann–Whitney test for independent samples.
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groups are presented in Supplementary Table 2.
Identification of urinary peptides associated with CKD
Analysis of urine from all dogs in the discovery group
resulted in identification of 5398 different peptides (Fig. 1a–b).Table 1
Peptide sequences of thirty-five urinary peptides, differentially excreted between heal
Peptide ID Peptide sequence Prote
1118 DGRpGPpGPpG Colla
1287 GDRGEpGPpGP Colla
2544 GPpGESGREGSpG Colla
2873 ApGDRGEpGPpGP Colla
4264 ApGDRGEpGPpGPAG Colla
5134 DGQPGAKGEpGDAGAK Colla
5497 GSpGSpGPDGKTGPPGp Colla
6130 SpGSpGPDGKTGPpGPAG Colla
6513 VGpPGPpGPpGPPGPPSGG Colla
6662 VGpPGPpGPpGPpGPPSGG Colla
6802 DQGPVGRTGETGASGpPG Colla
7219 NGApGNDGAKGDAGApGApG Colla
8115 GEKGPSGEpGTAGPpGTpGP Colla
8907 SGGIIDQSRVLNLGPITR Urom
9040 TGEKGpSGEpGTAGPpGTpGP Colla
9966 SGGIIDQSRVLNLGPITRK Urom
11110 AGPpGEAGKpGEQGVPGDLGApGP Colla
11265 AGPpGEAGKpGEQGVpGDLGApGP Colla
11289 GPpGpPGGMKGEKGEQGEPGKR Colla
11294 PGpDGKTGPPGPAGQDGRPGPPGP Colla
11526 RGAPGDRGEpGPpGPAGFAGppGA Colla
11728 FTGEKGPSGEpGTAGPpGTPGpQG Colla
13263 LDGAKGDAGPAGPKGEpGSpGENGApG Colla
14251 VNGApGEAGRDGNpGNDGPpGRDGQAG Colla
14554 pGDKGEAGPSGpAGpTGARGApGDRGEP Colla
14824 AGPpGApGApGAPGPVGPAGKNGDRGETGP Colla
14848 KEGGKGARGETGPAGRpGEVGPpGPpGP Colla
15775 GSRGDGGppGATGFPGAAGRTGPpGpSGITG Colla
17053 NGPpGPAGSRGDGGpPGATGFpGAAGRTGpPGP Colla
18031 LDGAKGDAGPAGPKGEpGSpGENGApGQMGPRG Colla
19095 GADGQPGAKGEpGDAGAKGDAGPpGPAGPTGPpGPIG Colla
19687 AAGEpGKAGERGVPGppGAVGPAGKDGEAGAQGPPGP Colla
19943 GpAGVRGPNGDSGRPGEPGLmGpRGFPGAPGNVGp Colla
20535 ARGNDGATGAAGPpGPTGPAGPpGFpGAVGAKGEAGpQG Colla
20952 GPpGADGQPGAKGEpGDAGAKGDAGpPGPAGPTGPpGPIG Colla
p, hydroxyproline; k, hydroxylysine; m, hydroxymethionine.
a Wilcoxon rank sum test.
b P-value adjusted using the method described by Benjamini and Hochberg, 1995.Comparison of canine urine from healthy dogs and
dogs with CKD in the discovery group, after correction for
multiple testing, identified 133 differentially excreted
peptides. These 133 peptides were combined in an SVM model
(133P). The score given to each dog, by this model, significantly
separated healthy dogs and dogs with CKD in the discovery
cohort (Fig. 2a).thy dogs and dogs with chronic kidney disease (CKD) in the discovery cohort.
in name UniProt Name Pa Adjusted Pb
gen alpha-1(I) chain CO1A1_CANLF 0.00105003 0.0112353
gen alpha-1(I) chain CO1A1_CANLF 0.00618982 0.03679507
gen alpha-1(I) chain CO1A1_CANLF 0.00897202 0.04465147
gen alpha-1(I) chain CO1A1_CANLF 0.00794034 0.04212972
gen alpha-1(I) chain CO1A1_CANLF 0.00030786 0.00732031
gen alpha-1(I) chain CO1A1_CANLF 0.00369059 0.02755065
gen alpha-1(I) chain CO1A1_CANLF 0.00049369 0.00880411
gen alpha-1(I) chain CO1A1_CANLF 0.00057598 0.00897333
gen alpha-1(I) chain CO1A1_CANLF 0.00161971 0.015292
gen alpha-1(I) chain CO1A1_CANLF 0.00479476 0.03173438
gen alpha-2(I) chain CO1A2_CANLF 0.00042247 0.00874917
gen alpha-1(I) chain CO1A1_CANLF 0.0024626 0.02107989
gen alpha-2(I) chain CO1A2_CANLF 0.00022146 0.00681417
odulin UROM_CANLF 6.8368E-05 0.00337633
gen alpha-2(I) chain CO1A2_CANLF 0.00078021 0.00963253
odulin UROM_CANLF 0.00049369 0.00880411
gen alpha-1(I) chain CO1A1_CANLF 0.00105003 0.0112353
gen alpha-1(I) chain CO1A1_CANLF 0.00545214 0.03431641
gen alpha-5(IV) chain CO4A5_CANLF 0.00322672 0.02468753
gen alpha-1(I) chain CO1A1_CANLF 0.00618982 0.03679507
gen alpha-1(I) chain CO1A1_CANLF 0.00545214 0.03431641
gen alpha-2(I) chain CO1A2_CANLF 6.8368E-05 0.00337633
gen alpha-1(I) chain CO1A1_CANLF 2.7983E-05 0.00337633
gen alpha-2(I) chain CO1A2_CANLF 0.00369059 0.02755065
gen alpha-1(I) chain CO1A1_CANLF 0.00420995 0.02970094
gen alpha-1(I) chain CO1A1_CANLF 0.0101218 0.04885862
gen alpha-1(I) chain CO1A1_CANLF 5.6936E-05 0.00337633
gen alpha-2(I) chain CO1A2_CANLF 1.9352E-05 0.00337633
gen alpha-2(I) chain CO1A2_CANLF 0.00018795 0.00639273
gen alpha-1(I) chain CO1A1_CANLF 0.00102315 0.0112353
gen alpha-1(I) chain CO1A1_CANLF 0.00078021 0.00963253
gen alpha-1(I) chain CO1A1_CANLF 8.134E-05 0.00373003
gen alpha-2(I) chain CO1A2_CANLF 0.00161971 0.015292
gen alpha-1(I) chain CO1A1_CANLF 6.786E-05 0.00337633
gen alpha-1(I) chain CO1A1_CANLF 0.004748 0.03173438
Fig. 3. Validation of urinary peptide models in an independent, masked cohort. Classification of healthy dogs and dogs with chronic kidney disease (CKD) in the validation
cohort according to (a) 133P model scores and receiver operating characteristic (ROC) curve for the 133P model (area under the curve [AUC] 0.88; 95% confidence intervals [CI],
0.721–1.04); (b) 35P model scores and ROC curve for the 35P model (AUC 0.88; 95% CI, 0.723–1.04). **, P < 0.01 vs. healthy dogs, Mann–Whitney test for independent samples;
#, P < 0.005.
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Sequence information was obtained for 35 out of the 133
differentially excreted urinary peptides. Thirty-three of them were
fragments of collagen (I and IV) and two of them were uromodulin
fragments (Table 1). All 35 peptides were present in lesser
(normalized) amounts in dogs with CKD (Fig. 1c). These 35
peptides were combined in a second SVM model (35P), which
significantly separated healthy dogs and dogs with CKD in the
discovery cohort (Fig. 2b).
Validation of 133P and 35P models
Masked validation was performed by scoring the dogs as
‘healthy’ or ‘CKD’ using both models. A positive score (>0) was used
to predict CKD. After unmasking, these predictions were compared
to the clinical status of the dog. The distribution of 133P and 35P
scores showed significant separation of healthy dogs and dogs with
CKD; the 133P model predicted CKD with a sensitivity of 80% (95%
confidence interval [CI], 44–97), a specificity of 80% (CI: 44–97) and
an AUC of 0.88 (CI: 0.72–1.0; Fig. 3a). The 35P model predicted CKD
with a sensitivity of 70% (CI: 35–93), a specificity of 80% (CI: 44–97)
and an AUC of 0.88 (CI: 0.72–1.0; Fig. 3b).
Discussion
In the present study, urinary peptide biomarkers of CKD in dogs
were identified using a mass spectrometry-based approach. To our
knowledge, this is the first time that canine urinary peptide
markers have been identified for CKD. Combination of thesepeptides in two different mathematical models composed of either
all significant peptides, or only sequenced peptides, predicted CKD
with an area under the ROC curve of 0.88 (95% CI, 0.72–1.0) in an
independent validation cohort. Multiple marker-methods may
identify complex processes (such as renal fibrosis) better than
single-marker methods do (Fliser et al., 2007). It is therefore
possible that this technology may represent a useful additional
diagnostic tool for early detection of CKD in the dog, similar to the
human counterpart model CKD273. An additional highly impor-
tant clinical issue is whether CKD in an individual dog is
progressive or not. There is initial evidence that CKD273,
constructed under similar conditions as those in the present
study, is associated with CKD progression (Schanstra et al., 2015).
Therefore it is possible that the canine peptide models identified in
the present study have similar characteristics. This will need to be
confirmed in a cohort for which longitudinal clinical follow-up is
available.
Most of the sequenced peptides associated with canine CKD
were collagen I fragments, which were less abundant in the
urine of dogs with CKD than in the urine of healthy dogs. This is
in agreement with studies in human CKD (Rossing et al., 2008;
Good et al., 2010). It is hypothesized that decreased urinary
collagen fragments are associated with decreased collagenase
activity and increased intrarenal extra-cellular matrix (ECM)
deposition (Rossing et al., 2008). Intrarenal ECM deposition
leading to fibrosis is the common final pathway in many kinds of
CKD across species, including human (Rossing et al., 2008; Good
et al., 2010), and therefore this reasoning most likely also holds
true in dogs. Furthermore, a recent study showed a significant
association between CKD273 score and degree of fibrosis in
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scores are associated with ongoing fibrosis in CKD, this
diagnostic modality would detect something entirely different
than the current clinical standards (assessment of GFR by
measurement of circulating indirect biomarkers such as serum
creatinine, urinalysis and imaging) do, and consequently
represent a completely new non-invasive diagnostic option.
Therefore, this technique should be further validated in future
studies.
Limitations of this study include the small validation group and
lack of evaluation of biological variation of the peptide models. A
further validation study is planned to investigate the performance
of these models. This study will also allow evaluation of the
potential impact of urine sampling technique (cystocentesis vs.
free catch) on results of CE–MS analysis in canine urine and to
further sequence all differentially excreted peptides identified in
the present study.
In this study, 3 dogs with suspected glomerulopathy
(UPC >3–4), were included. The resultant heterogeneity of the
CKD groups may have influenced the results. However, because
proteins >20 kDa are removed before analysis, this is probably not
of major importance.
Because of the limited number of dogs within different stages of
CKD in this study, dogs were not randomly allocated to discovery
and validation cohorts. Instead, dogs were grouped with the
intention to obtain similar average degree of severity of CKD in
both groups. This way a large discrepancy regarding severity of
CKD between the two cohorts was avoided.
Conclusions
Urinary peptide based models were able to discriminate
healthy dogs from dogs with CKD in an independent cohort of
20 dogs. Thirty-five of the 133 peptides differentially expressed
between healthy dogs and dogs with CKD were sequenced, and
most of them were collagen fragments. Peptidome analysis by CE–
MS is a promising future additional tool for diagnosis of canine
CKD, but further investigations are necessary in order to validate
the usefulness of these models for early CKD diagnosis and
prediction of progression in a clinical setting.
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